KROS - Keros potential drug for high blood pressure in lungs KER-012 shows tolerability in healthy people in interim data

Keros Therapeutics (NASDAQ:KROS) said preliminary data from part 1 of its phase 1 trial of KER-012 in healthy postmenopausal volunteers showed that the drug was well tolerated. Lexington, Mass.-based Keros is exploring KER-012 as a treatment for pulmonary arterial hypertension (PAH) — a type of high blood pressure which affects the arteries in the lungs and the heart — which is associated with reduced bone morphogenetic protein (BMP) signaling. The company believes KER-012 has the potential to increase the signaling of BMP pathways by inhibiting activin A and activin B signaling and treat diseases such as PAH. In part 1 of the study, 32 people received either a single 0.75, 1.5, 3 or 5 mg/kg dose of KER-012 and eight people received a single dose of placebo, each given subcutaneously with an eight-week safety follow-up. The company said KER-012 was generally well tolerated in part 1 of the trial at dose levels up to

For further details see:

Keros potential drug for high blood pressure in lungs KER-012 shows tolerability in healthy people in interim data